BRIEF—Hookipa Pharma eyes $86 million IPO

Hookipa Pharma has submitted a prospectus for an $86 million initial public offering (IPO) on the Nasdaq stock exchange, weeks after announcing it had raised nearly $40 million in a series D round.

The US and Austrian oncology and infectious disease specialist is backed by the Boehringer Ingelheim Venture Fund, Takeda Ventures, and others.

The firm is developing arena-virus based vaccination technology, VaxWave and TheraT, to try to develop more effective T-Cell immunotherapies.

In infectious diseases, the firm’s lead candidate is HB-101, in Phase II testing. In oncology Hoopika has HB-201 and HB-202, both of which are due to enter clinical stage testing this year.